CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening
Genetic Testing · 2008-03 · 12 (1) · 25-35
DOI: 10.1089/gte.2007.0046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Genetic Testing, 2008-03. Verfasst von Phillis Lakeman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands. p.lakeman@vumc.nl. Hauptthemen laut MEDLINE: Mutation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
AIMS: To obtain more insight into the variability of the CFTR mutations found in immigrant cystic fibrosis (CF) patients who are living in Europe now, and to estimate the test sensitivity of different frequently used methods of DNA analysis to detect CF carriers or patients among these Turkish or North African immigrants. METHODS: A survey among 373 European CF centers asking which CFTR mutations had been found in Turkish and North African CF patients. RESULTS: 31 and 26 different mutations were reported in Turkish and North African patients, identifying 64.2% (113/176) and 87.4% (118/135) alleles, respectively (p < 0.001). The mean sensitivity (detection rate) of three most common CFTR mutation panels to detect these mutations differed between Turkish and North African people, 44.9% (79/176) versus 69.6% (94/135) (p < 0.001), and can be increased to 57.4% (101/176) and 79.3% (107/135) (p < 0.001), respectively, by expanding these panels with 13 mutations which have been found on two or more alleles. CONCLUSION: 35.8% and 12.6%, respectively, of CF alleles in Turkish and North African patients living in Europe now had not been identified. Among these populations, the test sensitivity of common CFTR mutation panels is insufficient for use in screening programs in Europe, even after expansion with frequent Turkish and North African mutations. This raises questions about whether and how to implement CF carrier and neonatal screening in a multiethnic society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands. p.lakeman@vumc.nl
Zitieren
APA
Lakeman, P., Gille, J. J., Dankert-Roelse, J. E., Heijerman, H. G., Munck, A., Iron, A., Grasemann, H., Schuster, A., Cornel, M. C., & Ten Kate, L. P. (2008). CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening. Genetic Testing, 12(1), 25-35. https://doi.org/10.1089/gte.2007.0046
Vancouver
Lakeman P, Gille JJ, Dankert-Roelse JE, Heijerman HG, Munck A, Iron A, et al. CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening. Genetic Testing. 2008;12(1):25-35. doi:10.1089/gte.2007.0046
BibTeX
@article{Lakeman2008,
author = {Lakeman, Phillis and Gille, Johan J P and Dankert-Roelse, Jeannette E and Heijerman, Harry G M and Munck, Anne and Iron, Albert and Grasemann, Hartmut and Schuster, Antje and Cornel, Martina C and Ten Kate, Leo P},
title = {CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening},
journal = {Genetic Testing},
year = {2008},
volume = {12},
number = {1},
pages = {25--35},
doi = {10.1089/gte.2007.0046}
}
EUVIMED